Open AccessRelationship between clinical remission of perianal fistulas in Crohn’s disease and serum adalimumab concentrations: A multi-center cross-sectional study
Author(s) -
Laura Sirmai,
Anne-Laure Pelletier,
Nathalie Gault,
Camille Zallot,
Guillaume Bouguen,
D. Bouchard,
Pascale Nicaise,
Marine Peyneau,
S. Sironneau,
Marcelo De Carvalho Bittencourt,
Antoine Petitcollin,
P. Fernandez,
Xavier Roblin,
L. Siproudhis,
Laurent Abramowitz
Publication year - 2022
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v28.i9.961
Subject(s) - medicine , adalimumab , fistula , crohn's disease , gastroenterology , magnetic resonance imaging , single center , cross sectional study , cohort , surgery , disease , pathology , radiology
Crohn's disease (CD) is complicated by perianal fistulas in approximately 20% of patients. Achieving permanent fistula closure remains a challenge for physicians. An association between serum anti-tumor necrosis factor-α concentrations and clinical outcomes in patients with CD has been demonstrated; however, little information is available on serum adalimumab (ADA) concentrations and remission of perianal fistulas in such patients.